Introduction
Nuclear factor-kappaB (NF-kB) proteins are transcription factors that play an important role in regulating gene expression, differentiation and survival in normal B cells (Schmitz et al., 2004) . In humans, the family comprises p50/p105 (NF-kB1), p52/p100 (NF-kB2), p65 (RelA), c-Rel and RelB. The most common form of NF-kB is the p65:p50 heterodimer. In most cell types, NF-kB proteins exist in an inactive state as homodimers or heterodimers bound to inhibitory IkB proteins (e.g., IkB a, b, g, e) in the cytoplasm. Diverse stimuli, including tumour necrosis factor (TNF)-b, lipopolysaccharide, CD40L and B cell receptor (BCR) stimulation, activate a multisubunit IkB kinase (IKK), which phosphorylates and triggers proteasome-dependent degradation of IkB-a, the predominant IkB inhibitory molecule. NF-kB then translocates to the nucleus where it modulates transcription by binding to specific DNA sequences in target promoters. Direct modification of NF-kB subunits through phosphorylation (at least in part catalysed by IKK) and acetylation also modulates transcriptional activity. Other mechanisms of activation have also been described. For example, B cell-activating factor belonging to the TNF family (BAFF) is thought to activate NF-kB via an alternative pathway involving proteolytic processing of p100, the precursor for p52 (Claudio et al., 2002; Kayagaki et al., 2002) .
There are multiple mechanisms by which NF-kB can promote cell survival. Target genes induced by NF-kB that are important for controlling cell survival include inhibitors of caspases (e.g., cellular inhibitor of apoptosis-1 (cIAP-1) and cIAP-2), Bcl-2 family proteins (e.g., Bcl-X L and Bfl-1) and signalling molecules (e.g., TNF receptor-associated factor (TRAF)1 and TRAF2) (LaCasse et al., 1998; Lee et al., 1999; Grad et al., 2000) . NF-kB also induces the expression of A20, which functions to inhibit signalling via the TNFa receptor (Ravid and Hochstrasser, 2004) . Another potential cell survival pathway is inhibition of proapoptotic c-jun NH 2 -terminal kinase (JNK) pathway activity, in part mediated via transactivation of GADD45b and inhibition of mitogen-activated protein kinase kinase 7 (MKK7)/JNKK2 kinase (Papa et al., 2004) . However, there are thought to be many NF-kB target genes (possibly 200-300) and other pathways may contribute in specific cell types.
Chronic lymphocytic leukaemia (CLL) is the most common B-cell malignancy in the Western world and is characterized by the accumulation of CD5-positive monoclonal B cells in the blood, bone marrow and peripheral lymphoid organs (Caligaris-Cappio and Hamblin, 1999) . CLL is generally described as a disease of failed apoptosis, which is likely to stem in part from cell autonomous (e.g., genetic/epigenetic) alterations in cell death control molecules. However, CLL cells undergo apoptosis when removed from the body and in vivo environment-derived survival signalling is also considered to play major role in the etiology of this disease (Ghia and Caligaris-Cappio, 2000; Packham and Stevenson 2005) . Identification of CLL survival pathways may provide novel therapeutic opportunities as it may be possible to inactivate these molecules to promote CLL apoptosis.
Constitutive NF-kB activation contributes to inappropriate cell survival in a wide range of human malignancies (Orlowski and Baldwin, 2002; Perkins 2004) and there is increasing evidence that NF-kB may also play a key role in controlling apoptosis in CLL. Previous studies have demonstrated that CLL cells express abundant levels of nuclear NF-kB DNA-binding activity, often elevated compared to normal B cells (Romano et al., 1998; Sembries et al., 1999; Furman et al., 2000; Bernal et al., 2001; Munzert et al., 2002; Zaninoni et al., 2003; Cuni et al., 2004) . Although the levels of activated NF-kB were not determined directly, Rodriguez et al. (2004) demonstrated variations in the levels of phosphorylated IkBa in malignant lymph nodes derived from CLL patients. Importantly, the expression of NF-kB appears to be linked to environmental signalling pathways. For example, NF-kB activity in CLL cells is downregulated during ex vivo culture (Furman et al., 2000; Bernal et al., 2001; Cuni et al., 2004) , suggesting its activity is driven, at least in part, by in vivo signals. Consistent with this, cytokines and signalling via the B-cell receptor, which can promote the survival of CLL have been associated with induction of NF-kB (Romano et al., 1998; Furman et al., 2000; Bernal et al., 2001; Zaninoni et al., 2003; Cuni et al., 2004; Petlickovski et al., 2005) . NF-kB is also downregulated following treatment with dexamethasone or fludarabine, which accelerate CLL cell apoptosis ex vivo, suggesting it is important target for these therapeutic agents (Romano et al., 1998; Furman et al., 2000) .
Taken together, these studies have provided compelling evidence that NF-kB is likely to play an important role in the survival of CLL cells. However, much of this work is correlative. It is important to note that in some circumstances NF-kB can actually promote cell death (Perkins, 2004) and that previous microarray analyses (Shaffer et al., 2002) have failed to identify a gene expression signature indicative of NF-kB activation in CLL cells. Only one study in a very limited number of cases has attempted to determine directly the importance of NF-kB for CLL survival, demonstrating that incubation of cells with a kB binding site decoy to inhibit NF-kB-mediated transcription increased CLL apoptosis (Romano et al., 1998) .
The aim of this study was to use pharmacological inhibitors to investigate the function of NF-kB in CLL.
We determined whether inhibitors increased spontaneous apoptosis of CLL cells and normal B cells cultured ex vivo, and whether sensitivity of CLL cells correlated to clinical markers of disease subtype. We also investigated the downstream effects of NF-kB inhibition in CLL. Our results confirm that NF-kB contributes to cell survival in a significant proportion of CLL samples via inhibition of the intrinsic cell death pathway and support the hypothesis that NF-kB inhibitors may have clinical utility in CLL.
Results
Effect of NF-kB pathway inhibitors on survival of CLL and normal B cells CLL cells from the peripheral blood of 21 patients were treated with pharmacological inhibitors of the NF-kB pathway. We also analysed the effects of these inhibitors on the survival of cells isolated from the spleens of two patients with splenic involvement. Clinicopathological details of the patients are shown in Table 1 . All pharmacological inhibitors potentially suffer from lack of selectivity and off-target effects, and we therefore used two distinct NF-kB pathway inhibitors, BAY110782 (BAY) and Kamebakaurin (KA). BAY is a very well-characterized synthetic inhibitor of IKK (Pierce et al., 1997) , whereas KA is a complex natural kaurane diterpene that directly inhibits DNA binding by NF-jB function in CLL BM Pickering et al p50 . Although KA is less well studied, it was included in the study as its mechanism of action is distinct from BAY. Both compounds are ranked as reliable inhibitors of NF-kB in ChemBank (http:// chembank.broad.harvard.edu/), and as the compounds are mechanistically and structurally distinct, a close correlation between their effects in different samples would provide very strong evidence that they were exerting their effects as NF-kB inhibitors. In contrast, if there were significant differences in sensitivity of individual samples to the two compounds, it would be likely that this was owing to off-target effects (or potentially, NF-kB-independent functions of IKK, which would be affected by BAY, but not KA).
Cells were incubated with compounds for 6 h and the extent of apoptosis determined by measuring the increase in poly-ADP-ribose polymerase (PARP) cleavage compared to control (solvent-treated) cells at that time. PARP is a nuclear protein that is cleaved by caspases during apoptosis. The 6 h time point was selected because significant levels of spontaneous apoptosis were not detected in the majority of CLL samples at this time. Overall, 16/23 (70%) of CLL samples were considered sensitive to NF-kB pathway inhibitors (the cutoff for sensitivity was arbitrarily set at X25% PARP cleavage induced by 2 mM BAY and/or 6 mM KA; Figure 1 and Table 2 ). The induction of apoptosis by each inhibitor was generally dose dependent. Analysis of Annexin V exposure confirmed induction of apoptosis in NF-kB pathway inhibitortreated cells (data not shown). Importantly, there was a very good correlation between the sensitivity to the two inhibitors (Spearman's correlation r ¼ 0.8400, Po0.0001), providing excellent evidence that these inhibitors exert their effects in CLL cells via selective inhibition of the NF-kB pathway.
CLL is a heterogeneous disease, and we compared the levels of apoptosis induced by BAY and KA to prognostic markers, V H gene status, Zap70 and CD38 expression. The absence of somatic mutations in the immunoglobulin V H genes (Damle et al., 1999; Hamblin et al., 1999) , high levels of cell surface CD38 (Damle et al., 1999; Morabito et al., 2001; Hamblin et al., 2002) and presence of Zap70 (Rosenwald et al., 2001 , Crespo et al., 2003 , Wiestner et al., 2003 are associated with a poor prognosis. Although there was a tendency for higher levels of apoptosis in CLL lacking V H mutations (U-CLL) compared to CLL with mutated V H genes (M-CLL) for both inhibitors (mean PARP cleavage for U-CLL and M-CLL cells for BAY was 41 and 28%, mean PARP cleavage for U-CLL and M-CLL cells for KA was 37 and 23%), there was considerable overlap in the levels of PARP cleavage in individual cases within these two groups and these differences were not statistically significant (P>0.05; Student's t-test). There was also no correlation between CD38 or Zap70 positivity and sensitivity to BAY or KA (P>0.05; Student's t-test).
We also determined the effects of NF-kB pathway inhibitors on survival of normal B cells isolated from peripheral blood of three healthy donors. KA and BAY did not induce PARP cleavage in normal B cells when tested at concentrations that induced apoptosis in the majority of CLL samples (Figure 2 ). Thus, normal peripheral blood B cells were relatively resistant to the effects of NF-kB pathway inhibitors.
Analysis of NF-kB DNA-binding activity in CLL We analysed NF-kB DNA-binding activity in CLL samples. Although there was modest variation in the relative levels, NF-kB activity was readily detected in all samples analysed (Figure 3a) , confirming results of previous studies (Romano et al., 1998; Sembries et al., Table 2 for summary of all data. 1999; Furman et al., 2000; Bernal et al., 2001; Munzert et al., 2002; Zaninoni et al., 2003; Cuni et al., 2004) . Electrophoretic mobility shift assays and supershift analysis demonstrated that the complexes mainly comprised p65, p50 and c-Rel, with little RelB or p52 (Figure 3b and 3c ). The assay also demonstrated approximately equivalent levels of CBF-1, a transcription factor that interacts with a binding site overlapping the NF-kB consensus site in this probe and can influence basal expression of the IkBa gene (Oakley et al., 2003) . We compared the relative abundance of nuclear NF-kB with the sensitivity to NF-kB pathway inhibitor-induced apoptosis. However, there was no correlation between the levels of NF-kB detected by enzyme-linked immunosorbant assay (ELISA) and percent apoptosis induced by either BAY or KA (Spearman's correlation r ¼ 0.1820, P ¼ 0.51 and r ¼ 0.2412, P ¼ 0.3682, respectively).
Activation of caspases during NF-kB pathway inhibitor induced apoptosis
To investigate the apoptosis pathways activated by NF-kB pathway inhibitors, we analysed the activation of caspases in BAY-or KA-treated CLL cells. Consistent with cleavage of the caspase-3 substrate, PARP-, BAY-and KA-induced apoptosis was associated with the processing and activation of the effector caspase-3, demonstrated by the disappearance of inactive procaspase-3 and accumulation of active caspase-3 cleavage products ( Figure 4a ). Caspase-3 activation was detectable B4 h following the addition of inhibitor. In some experiments, caspase-3 was completely absent at later time points, consistent with additional proteolytic cleavage. BAY-or KA-induced apoptosis was also associated with the activation (processing) of the initiator procaspase-9, which is activated following the release of cytochrome c from the mitochondria (the intrinsic pathway). By contrast, there was no evidence for activation of caspase-8, normally activated following ligand binding to cell surface death receptors (the extrinsic pathway). Therefore, the activation of caspase-3 is most likely to be caused by caspase-9-mediated processing. Although we do not exclude the possibility that NF-kB pathway inhibition results in low-level activation of the caspase-8/extrinsic pathway, these data suggest a predominant role for NF-kB in preventing the activation of the intrinsic mitochondrial apoptosis pathway in CLL cells. Consistent with this, we detected a significant decrease in mitochondrial membrane polarization, a marker of mitochondrial function associated with cytochrome c release/intrinsic apoptosis (Brenner et al., 2003) in BAYtreated CLL cells (Figure 4b ). Regulation of Bcl-2 and Mcl-1 protein expression by NF-kB pathway inhibitors Bcl-2 family survival proteins play a central role in controlling CLL apoptosis, and function, at least in part, by suppressing the intrinsic apoptosis pathway. For example, Bcl-2 and Mcl-1 are important for constitutive survival and enhanced survival of CLL cells, respectively (Pepper et al., 1999; Pedersen et al., 2002) . Bcl-2 has previously been described as an NF-kB target gene and the activation of Bcl-3, which can occur in a subset of CLL has also been demonstrated to increase Bcl-2 expression (Viatour et al., 2003; Feuillard et al., 2000) . We therefore determined whether apoptosis induced by NF-kB pathway inhibitors was associated with changes in the expression of Mcl-1 or Bcl-2. Immunoblot analysis demonstrated that despite induction of apoptosis, the overall expression of Bcl-2 and Mcl-1 was unaltered ( Figure 5 ). There was evidence for the accumulation of cleaved forms of Mcl-1, but these are generated by caspase cleavage rather than a primary response to NF-kB pathway inhibitors (Michels et al., 2004) .
Role of JNK in CLL apoptosis induced by NF-kB pathway inhibitors
To investigate the effects of NF-kB pathway inhibitors on JNK activity, we analysed the amount of Ser63-phosphorylated c-jun, a downstream target phosphorylated by JNK. Consistent with a role of NF-kB in suppressing JNK activity in CLL, incubation with NF-kB pathway inhibitors, in particular BAY, caused an increase in c-jun phosphorylation ( Figure 6 ). To determine whether JNK activity was required for apoptosis induced following NF-kB inhibition, we coincubated BAY-or KA-treated cells with a JNK inhibitor. As expected, NF-kB inhibition alone increased PARP cleavage and the JNK inhibitor decreased the levels of c-jun phosphorylation. However, the JNK inhibitor did not decrease BAY-or KAinduced PARP cleavage (and in fact moderately enhanced cell death). Therefore, although NF-kB pathway inhibitors led to the activation of JNK in CLL cells, this is not critical for NF-kB pathway inhibitor induced apoptosis.
Identification of some novel NF-kB-regulated genes in CLL NF-kB is a transcription factor and we therefore performed a gene expression microarray experiment to identify potential NF-kB-regulated genes in CLL cells. This experiment was performed using one of the spleen samples (patient 23) because it was relatively easy to isolate highly purified B cells isolated by negative selection from this patient's sample, but candidate regulated genes were subsequently confirmed in a larger set of samples (see below). Cells were treated with 2 mM BAY for 6 h and alterations in gene expression analysed by microarray analysis. Approximately 470 genes were differentially regulated by at least twofold (B150 genes upregulated and B320 genes downregulated). At a more stringent fourfold cutoff, 13 genes were upregulated and 25 genes were downregulated (Table 3) . Notably, 'classic' NF-kB target genes were not significantly regulated in this experiment; the expression of Bcl-X L , Bfl-1, A20 and cIAP-1 was 1.14, 0.79, 1.02 and 1.04, respectively, in BAY-treated cells relative to dimethylsulphoxide (DMSO)-treated cells. As the microarray experiment was performed using a single sample, the regulated genes are likely to represent only a subset of all NF-kB-regulated genes, and additional targets might be identified in further array experiments using additional samples. However, it would be important to identify even a subset of new target genes and we therefore used quantitative reverse transcription- NF-jB function in CLL BM Pickering et al polymerase chain reaction (Q-RT-PCR) to determine whether these putative target genes were consistently regulated in a panel of CLL samples, and also by KA. Genes were selected for further analysis because of their potential role in cell survival, signalling or NF-kB regulation. Bcl-w is an antiapoptotic Bcl-2 family protein (Scorrano and Korsmeyer, 2003) , Bcl-2-associated athanogene (BAG)3 is an Hsc70/Hsp70 cochaperone survival molecule (Takayama and Reed, 2001 ), interleukin (IL)-16 is a regulator of T-cell proliferation and apoptosis (Wilson et al., 2004) and HSPC195 is a novel regulator of NF-kB (Matsuda et al., 2003) . We analysed four CLL samples from peripheral blood, using both BAY and KA to confirm that any changes were a consistent response to NF-kB pathway inhibitors. We also analysed the two CLL samples isolated from spleens, including a second experiment performed with sample 23, used in the original microarray analysis. All of these samples were considered sensitive to NF-kB pathway inhibitors.
Consistent with the microarray data, Bcl-w, HSPC195 and IL-16 were downregulated, and BAG3 was upregulated by BAY in the repeat experiment using sample 23 (Table 4) . Similar results were obtained with KA, which decreased the expression of Bcl-w below the level of detection. Overall, BAG3 was induced, and IL-16 and HSPC195 decreased by both inhibitors in all of the samples studied. Bcl-w was downregulated by both inhibitors in 4/6 samples. In the other two samples, expression was decreased by one inhibitor, but induced by the other. Therefore, we have identified some novel NF-kB-responsive genes in CLL. We also performed Q-PCR analysis of 'classic' NF-kB targets Bfl-1, Bcl-X L , cIAP-1 and A20. Similar to the microarray experiment demonstrating that these genes were essentially unaltered, there was not a consistent pattern of regulation by BAY and KA across the majority of samples (data not shown).
Discussion
Previous studies have firmly established that CLL cells contain increased NF-kB-binding activity compared to normal B cells, and demonstrated a close correlation between changes in NF-kB activity and CLL survival (Romano et al., 1998; Sembries et al., 1999; Furman et al., 2000; Bernal et al., 2001; Munzert et al., 2002; Zaninoni et al., 2003; Cuni et al., 2004) . However, functional studies of NF-kB in CLL are limited (Romano et al., 1998) . Here, we have confirmed that NF-kB plays an important role in promoting the survival of at least a proportion of CLL cases. Overall, B70% of CLL samples were sensitive to NF-kB pathway inhibitors in this study. BAY and KA did not induce apoptosis in normal peripheral blood B cells, suggesting that CLL cells are relatively highly sensitive to the apoptosis-promoting effects of these compounds, although further studies will be required to investigate their effects in specific subsets of normal B cells. BAY and KA activated the intrinsic cell death pathway, but did not alter the expression of Bcl-2 or Mcl-1. Inhibition of NF-kB did lead to the activation of JNK, but this pathway was not required for apoptosis. Finally, we identified some novel potential NF-kB target genes.
The mechanisms that drive activation of NF-kB in CLL remain incompletely understood. Various cytokines, signalling via the B-cell receptor or from fibroblasts, have been demonstrated to increase CLL survival concomitant with enhanced activation of NF-kB (Romano et al., 1998; Furman et al., 2000; Bernal et al., 2001; Zaninoni et al., 2003; Cuni et al., 2004; Kern et al., 2004) . The precise factors important in vivo will be hard to unpick, and it is possible that a complex mixture of factors are involved. Induction of NF-kB by coculture on fibroblast was blocked by phosphatidylinositol-3 kinase inhibitors, implicating this key survival signalling kinase in this response (Ringshausen et al., 2002; Cuni et al., 2004) . Consistent with the idea that environmental signals play an important role in driving NF-kB activation in CLL (Schattner, 2000) , NF-kB levels gradually decay upon ex vivo culture of CLL cells (Bernal et al., 2001) . However, it is important to bear in mind that our experiments demonstrated rapid caspase activation (within 3-4 h) following the addition of NF-kB pathway inhibitors, and a significant loss of NF-kB owing to this natural decay associated with ex vivo culture within this time frame is unlikely, considering that NF-kB levels are maintained at significant levels for a considerable time (e.g., 9-12 h in Furman et al., 2000) .
It will be important to determine what features determine differences in sensitivity to these inhibitors between CLL samples, and between CLL and normal B cells. We confirmed previous findings demonstrating constitutive but variable levels of activation of NF-kB in CLL cells. These differences were not clearly correlated with sensitivity to NF-kB pathway inhibition. Thus, sensitivity may not simply be dictated by the relative levels of NF-kB in CLL, although it is important to bear in mind that the proportion of cases which were not sensitive to NF-kB pathway inhibitors was relatively small. There are many potential reasons why some cells may be resistant to the effects of NF-kB pathway inhibitors. For example, compounds may not inhibit NF-kB in these cells, for example, due to drug efflux or metabolism. Alternatively, although these cells contain NF-kB, they may have alternate survival pathways activated so that they are less affected by loss of NF-kB activity. Future studies will address these possibilities.
The sensitivity of CLL to NF-kB inhibitors did not correlate with prognostic markers CD38, Zap70 of V H mutation status. This suggests that NF-kB activity may not be a determinant of disease progression per se. However, we have suggested previously that interindividual variation in apoptosis susceptibility (possibly influenced by NF-kB) may be more closely associated with response to treatment (Packham and Stevenson, 2005) . It will be interesting therefore to identify whether sensitivity to NF-kB inhibitors is related to response to therapy, and whether NF-kB inhibitors sensitize CLL cells to conventional cytotoxics (Romano et al., 1998) .
We investigated the downstream molecular sequelae of NF-kB inhibition in CLL. Our results demonstrate a central role for NF-kB in suppressing the intrinsic cell death pathway in CLL cells, as NF-kB inhibition was associated with rapid activation of caspase-9 and loss of mitochondrial membrane polarization, with no detectable activation of caspase-8. Despite the important role of Bcl-2 and Mcl-1 as mitochondrial guardians in CLL, the expression of these key apoptotic regulators was unaltered in cells incubated with BAY or KA. Finally, although NF-kB appeared to play a significant role in inhibition of JNK (as NF-kB pathway inhibitors increased c-jun phosphorylation), this was not important for its prosurvival activity. Although JNK is proapoptotic in some cells, it may function as a survival signalling molecule in some B cells (Hess et al., 2002) .
We employed microarrays and Q-RT-PCR to determine the effect of NF-kB pathway inhibition on gene expression. Expression of 'classic' NF-kB target genes such as A20, Bfl-1, Bcl-X L or cIAP-1 was not consistently regulated in BAY-or KA-treated CLL cells. It is not possible to conclude that these genes are not dependent on NF-kB in CLL cells, as a decrease in transcription may not necessarily lead to a reduction in steady-state RNA expression within 6 h for relatively stable transcripts. However, these data indicate that these genes are unlikely to play a key role in NF-kBmediated survival in CLL. It is possible that the genes regulated by NF-kB, and required for NF-kB-mediated cell survival in CLL are distinct from 'classic' NF-kB target genes identified in other systems. Consistent with this, Munzert et al. (2002) demonstrated that some 'classic' target genes, such as X-linked inhibitor of apoptosis protein (XIAP), manganese superoxide dismutase, A20 and Bfl-1 were expressed more strongly in normal B cells compared to CLL cells, despite elevated NF-kB levels in CLL cells (Furman et al., 2000 , Zaninoni et al., 2003 . This may also explain why previous microarray analyses (Shaffer et al., 2002) have failed to identify an 'NF-kB gene expression signature', indicative of NF-kB activation in CLL cells, despite the clear presence of activated NF-kB in these cells. The effects of NF-kB on gene expression can be highly regulated. For example, prolonged versus acute NF-kB activation can result in the expression of different target genes. Specific gene regulation by NF-kB can also be influenced by differences in sub-unit expression, posttranslational modification, chromatin accessibility and differences in the levels of coactivators/corepressors or cooperating transcription factors (Natoli et al., 2005) . Thus, we hypothesize that some specific features of NF-kB in CLL, or the presence of modulating factors might result in the expression of a different subset of NF-kB target genes.
The array experiment was based on a single sample and was not designed to identify the full spectrum of NF-kB regulated-genes in CLL. However, it has provided important insight into NF-kB function in CLL as Q-RT-PCR analysis of selected genes in BAYor KA-treated cells has confirmed that at least some of the differentially regulated genes identified in this sample are consistently regulated in a panel of CLL samples, and by two mechanistically independent inhibitors. Consistent with the idea that at least some of the genes downregulated in BAY-treated cells were direct targets of NF-kB, we identified perfect matches (10 out of 10 positions) to the NF-kB binding site consensus (Natoli et al., 2005) in the promoter regions of the latent membrane protein (LMP)2, chemokine-like factor 3 and IL-16 genes, and good matches (eight or nine out of 10 matches) in the LMP7, CD79B, PEC-60 and Bcl-w genes. Predominant among the most differentially regulated genes, were genes involved in antigen processing, heat-shock response, survival and signalling.
BAY caused the downregulation of proteasome subunit PSMB9/LMP2 and PSMB8/LMP7, components of the immunoproteasome. Thus, NF-kB expression may modulate antigen presentation in CLL. This observation is consistent with the fact that LMP7 and LMP2 are upregulated by interferong, a known inducer of NF-kB. It also downregulated expression of CD79B, required for signalling via the BCR and IL-16, a regulator of T-cell proliferation and survival. As T-cell-mediated CD40 signalling is thought to provide important survival signals within CLL pseudofollicles (Granziero et al., 2001) , NF-kB may also indirectly modulate CLL survival by promoting survival-promoting interactions with immune effector cells. HSPC195 is a novel gene that is able to activate NF-kB by an unknown mechanism. Its downregulation may represent a feedback response to NF-kB inhibition. BAY also decreased BCL2L2/Bcl-w a prosurvival Bcl-2 family protein and HSPC195, which can act to increase NF-kB activity (Matsuda et al., 2003) . Decreased Bcl-w expressions may represent at least one pathway by which NF-kB inhibition promotes CLL apoptosis. Although the ability of NF-kB to transactivate Bcl-2 survival proteins (Bcl-X L , Bfl-1) is well established, NF-kB-mediated regulation of Bcl-w had not been described previously. A recent paper has confirmed that Bcl-w is regulated via NF-kB in gliomablastoma cells (Tran et al., 2005) .
Most strikingly, eight of the 13 genes induced by BAY X4-fold were involved in the heat-shock response. This included three DnaJ/Hsp40 proteins (DNAJB4, DNA-JA1 and DNAJB1), two Hsp70 proteins (HSPA1B and HSPA6) and SITP1/Hsp70/Hsp90-organizing protein/ HOP. BAY also increased the expression of BAG-3, a cochaperone that which associates with HSC70/HSP70 proteins (Takayama and Reed, 2001 ) and AHSA1, a cochaperone that stimulates HSP90 ATPase activity. HSPD1/HSP60 and HSPA2/HSP70 protein 2 were also induced by BAY, but below the fourfold cutoff (3.2-fold, P ¼ 0.018 and 2.2-fold, P ¼ 0.002, respectively). This observation is consistent with previous analyses demonstrating that pyrrolidinedithiocarbamate (another NF-kB inhibitor) induces a heat-shock response (DeMeester et al., 1998) and that NF-kB can interfere with the function of Heat shock factor-1 (HSF-1), a master regulator of the heat-shock response (Rossi et al., 1998) . The functional significance of this crosstalk is unclear, but may represent a potential cytoprotective response, or a feedback mechanism, as Hsp70 can inhibit IKK (Ran et al., 2004) . A recent study has demonstrated that the signalling kinase Zap70 is a client protein for Hsp90 in CLL (Castro et al., 2005) . Zap70 is a poor prognostic marker in CLL and can potentiate signalling via the BCR . Therefore, it will be interesting to investigate the effects of inhibition of NF-kB on BCR signalling capacity in CLL.
The ability of NF-kB inhibitors to promote apoptosis in the majority of CLL samples, but not normal B cells, suggests that NF-kB inhibitors may have clinical utility in the management of CLL. The inhibitors used in this study are useful experimental tools but are unlikely to be developed as drugs. However, a wide range of inhibitors are in development for various indications within the pharmaceutical industry and our findings support the idea that inhibition of the NF-kB pathway may have therapeutic utility in CLL. Although sensitivity to BAY and KA did not correlate with prognostic markers, the majority of 'poor prognosis CLL' (i.e., U-CLL, Zap70 positive and/or CD38 positive) were sensitive to NF-kB inhibition. Therefore, it may be particularly useful that NF-kB inhibitors could be used in this patient group, where new treatment options are especially needed.
Materials and methods

Cell isolation and culture
All studies on patients' material were performed with local research ethics committee approval and following informed consent. The study involved 21 samples isolated from peripheral blood and two CLL/small lymphocytic lymphoma samples isolated from splenectomies (Table 1) . V H status, CD38 and Zap70 expression was determined as described previously (Hamblin et al., , 2002 Wiestner et al., 2003) . Peripheral blood mononuclear cells were isolated by centrifugation using Lymphoprep (Nycomed Pharma AS, Oslo, Norway) and cryopreserved. Spleen samples were disaggregated and lymphocytes isolated by Ficoll-Paque centrifugation and cryopreserved as described (Dallman and Packham, 2005) . CLL samples were thawed and maintained at a density of 4-5 Â 10 6 cells/ml for 1 h at 371C in Rosewell's park memorial institute (RPMI)-1640 medium supplemented with 10% (v/v) fetal calf serum (FCS), 2 mM glutamine, 1% (w/v) sodium pyruvate, non-essential amino acids and antibiotics before use. The purity of B cells obtained was typically >98% (flow cytometry using anti-CD19 and anti-CD3 antibodies) and viability was >95% (Trypan blue exclusion). For the microarray experiment, B cells were purified by negative selection using the B-cell isolation kit (Miltenyi-Biotec, Bisley, UK) as described (Dallman and Packham, 2005) . The purity of B cells obtained was 99.4%. Normal B cells were isolated from the peripheral blood of healthy donors using Lymphoprep and negative selection using the B-cell isolation kit (MiltenyiBiotec, Bisley, UK).
Inhibitors JNK inhibitor II (SP600125; JNKi), BAY110782 (BAY) and KA were from Calbiochem (Nottingham, UK). All inhibitors were dissolved in DMSO and stored at À201C. Selection of concentrations was based on the literature and/or pilot experiments. An equivalent volume of DMSO was used in all experiments as a solvent control.
Immunoblot analysis
Immunoblotting was performed using whole-cell lysates prepared from equivalent cell numbers as described previously (Packham et al., 1997) using the following antibodies: anticaspase-3 (Cell Signaling Technologies, Beverly, MA, USA), anti-caspase-8 (3-1-9, BD Pharmingen, Oxford, UK), anticaspase-9 (Cell Signaling Technologies), anti-PARP (C2-10, R&D Systems, Abingdon, UK) and anti-phospho-Ser63 c-jun (Sigma, Poole, UK). For quantitation of PARP cleavage, digital images were captured using a BioRad Fluor-S multiimager and analysed using Quantity One software (BioRad, Hemel-Hempstead, UK). For each experimental point, the amount of cleaved (89 kDa) PARP cleavage was calculated as a percentage of total PARP (85 kDa þ intact 116 kDa PARP). The increase in PARP cleavage in cells incubated with inhibitors was the percentage of PARP cleavage in inhibitortreated cells minus the percentage of PARP cleavage in control (DMSO-treated) cells.
Mitochondrial membrane polarization
Loss of inner mitochondrial membrane polarization was determined by measuring the reduction in fluorescence from the mitochondrial reporter dye, 3,3 0 dihexyloxacarbocyanine (DiOC 6 (3), Molecular Probes, OS, US) (Zamzami et al., 1995) . DiOC 6 (3) (10 nM) was added to cells and incubated for 15 min at 371C in the dark. The cells were pelleted, washed and resuspended in phosphate-buffered saline1% FCS and analysed by flow cytometry (FL1).
Analysis of NF-kB DNA-binding activity Constitutive NF-kB activity was quantified by ELISA using the Trans-AM NF-kB p65 Transcription Factor Assay Kit (Active Motif, Rixensart, Belgium), according to the manufacturer's instructions. Briefly, nuclear extracts were prepared using the Nuclear Extract Kit (Active Motif) and incubated in 96-well plates coated with oligonucleotide containing an NF-kB consensus binding site. Bound NF-kB was detected by incubating with a p65-specific antibody followed by a horseradish peroxidase-conjugated secondary antibody, and quantified at 450 nm with a reference wavelength of 655 nm. Values were normalized for protein content.
For electrophoretic mobility shift assays, nuclear proteins were isolated from 10 Â 10 6 CLL cells using a modified
Dignam's method. DNA-binding activity was determined using an electrophoretic mobility shift assays and a radiolabelled double-stranded oligodeoxynucleotide containing an NF-kB consensus binding site (Promega, Southampton, UK) as described previously (Oakley et al., 2003) . Supershifts were performed as described previously (Oakley et al., 2003) .
Gene expression analysis
Total RNA was isolated using RNeasy minikit reagents (Qiagen, Crawley, UK). For Q-RT-PCR analysis, cDNA was generated using oligo(dT) and MMLV reverse transcriptase (Promega, Southampton, UK) according to the manufacturer's instructions. PCRs were performed in 25 ml reactions containing 5 ml cDNA, 10 ml 2Â Universal Taqman PCR master mix and 1 ml of Assays-on-Demand Taqman Gene Expression probes (Applied Biosystems, Foster City, CA, USA) of interest (Bfl-1, Bcl-xl, cIAP-1, A20, Bcl-w, HSPC195, IL-16, BAG3 and GAPDH). All reactions were performed in triplicate using the ABI PRISM 7900 Sequence detection System (Applied Biosystems, Warrington, UK) according to the following thermal cycle protocol: 941C 10 min, followed by 40 cycles of 941C for 15 s and 601C for 1 min. Control reactions with no cDNA added were run on each plate for each Taqman gene Expression Assay used and no amplification was detected in any control reaction. The GAPDH transcript level was used to normalize gene expression levels. Microarray analyses were performed using MWG human 40K A arrays comprising B20 000 probes, using duplicate arrays for control and BAY-treated cells (2 mM, 6 h). Array analysis was performed by the MWG hybridization service using standard protocols (MWG, Ebersberg, Germany). A mean was calculated for normalized expression values for all genes for replicate arrays. The fold change in expression was calculated by dividing the mean expression in control cells by the mean expression in BAY-treated cells. P-values were calculated using Student's t-tests.
